Deucravacitinib for Psoriasis

Jordan Valley Dermatology and Research Center, South Jordan, UT
PsoriasisDeucravacitinib - Drug
All Sexes

Study Summary

This trial studies how a drug can help improve quality of life for people with psoriasis.

Treatment Effectiveness

Phase-Based Effectiveness

3 of 3
Phase 4
This is further along than 93% of similar trials

Study Objectives

1 Primary · 7 Secondary · Reporting Duration: Up to week 56

At week 16
Proportion of participants who achieve Dermatology Life Quality Index (DLQI) score 0 or 1
Proportion of participants who achieve a ≥4-point reduction from baseline in DLQI
Baseline, Week 16
Change from baseline in whole-body itch Numerical Rating Scale (NRS) score at week 16
Up to week 56
Number of participants with adverse events (AEs)
Number of participants with clinical laboratory abnormalities
Number of participants with physical examination abnormalities
Number of participants with serious adverse events (SAEs)
Number of participants with vital sign abnormalities

Trial Safety

Phase-Based Safety

3 of 3
This is further along than 85% of similar trials

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2 Treatment Groups

1 of 2
Placebo then Deucravacitinib
1 of 2

Experimental Treatment

Non-Treatment Group

250 Total Participants · 2 Treatment Groups

Primary Treatment: Deucravacitinib · Has Placebo Group · Phase 4

Experimental Group · 1 Intervention: Deucravacitinib · Intervention Types: Drug
Placebo then DeucravacitinibPlaceboComparator Group · 2 Interventions: Deucravacitinib, Placebo · Intervention Types: Drug, Other
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 1

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to week 56

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,540 Previous Clinical Trials
4,019,331 Total Patients Enrolled
32 Trials studying Psoriasis
20,867 Patients Enrolled for Psoriasis

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a high score on a test that measures how much a skin condition affects your daily life.
Your doctor thinks that you may benefit from light therapy or medication.
You have had psoriasis for at least 6 months, and your condition has not worsened significantly recently according to the doctor.

Frequently Asked Questions

How many sites are currently executing this research trial?

"Arkansas Research Trials, Inc. in North Little Rock and Bakersfield Dermatology Skin Cancer Med.Group in Bakersfield are two of the 28 locations currently recruiting patients for this medical trial; Integrative Skin Science and Research in Sacramento is yet another participating site." - Anonymous Online Contributor

Unverified Answer

Are there any unoccupied slots in this investigation for participants?

"This particular trial is not accepting any new patients, as indicated by the listing which was last updated on January 26th 2023. However, there are 163 active studies that people can join at this time." - Anonymous Online Contributor

Unverified Answer

Could you discuss the degree of safety associated with Deucravacitinib?

"There is an abundance of evidence suggesting Deucravacitinib's safety, which earns it a 3 rating on our scale. This drug has reached approval status in the Phase 4 trial process." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.